Loading stock data…
Danaher Corporation (DHR)
$191.50-1.00 (-0.52%)
Market ClosedLast close Jul 24
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Danaher Corporation in the Healthcare sector is trading at $191.50 with a market capitalization of $134.6B. Wall Street consensus targets $227.61 (23 analysts), implying a +18.9% move over the next 12 months. The stock is currently 21% below its 52-week high of $242.80, remaining 5.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +18.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.95B↓ | $6.84B↑ | $6.05B↑ | $5.94B↑ | $5.74B |
| Gross Profit | $3.59B↓ | $3.97B↑ | $3.52B | $3.52B↑ | $3.51B |
| Operating Income | $1.34B↓ | $1.50B↑ | $1.15B↑ | $760.00M↓ | $1.27B |
| Net Income | $1.03B↓ | $1.20B↑ | $908.00M↑ | $555.00M↓ | $954.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$134.62B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
34.20
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.75%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.97%
Volume
Today's trading volume
5.96M
Recent News
Here's Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
The company delivered a mixed earnings report, but the sell-off looks like an overreaction.
Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises
EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.
6 Medical-Device Stocks to Buy After a Massive Selloff
Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.
Reading Between The Lines Of DHR's Latest Call
Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.
The 'Standout Performance' That Could Save Thermo Fisher, Danaher And Others
Thermo Fisher stock led a medtech rebound Thursday, easing investors' fears of continued malaise for the medical research and tools realm.